Article Data

  • Views 803
  • Dowloads 160

Original Research

Open Access

Prognostic factors and clinical hallmarks of low grade serous ovarian carcinoma: a single center study

  • Mohammad Zuhdy1
  • Mohamed Abdelkhalek1
  • Khaled Gaballa1
  • Mohamed Hamdy1
  • Basel Refky1,*,

1Surgical oncology department, Oncology Centre Mansoura University (OCMU), 35516 Mansoura, Egypt

DOI: 10.22514/ejgo.2023.104 Vol.44,Issue 6,December 2023 pp.98-104

Submitted: 06 April 2023 Accepted: 16 May 2023

Published: 15 December 2023

*Corresponding Author(s): Basel Refky E-mail: dr_basel@mans.edu.eg

Abstract

Ovarian cancer is the most fatal gynecologic malignancy. Low-grade type represents only 2–5% of all ovarian cancer pathological types. Its clinical characteristics, growth pattern, and response to treatment are distinct from high-grade serous ovarian carcinoma. In this study, we retrospectively evaluated the clinical features, prognostic factors, and survival of patients diagnosed with low-grade serous ovarian cancer from a tertiary cancer centre. This is a retrospective study where all patients diagnosed with low-grade serous ovarian cancer (LGSOC) who presented to a tertiary cancer centre from July 2015 to August 2021 were included. Forty-two patients with low-grade ovarian serous carcinoma were enrolled. The mean age of the patients was 50.17 ± 10.91 years, while the mean Body Mass Index (BMI) was 32.96 ± 6.02 kg/m2. Primary optimal debulking was performed in 18 patients, while interval cytoreduction was done in 17 patients. Suboptimal debulking was performed in 5 patients. Neoadjuvant chemotherapy was administered in 19 patients (45.2%). The median overall survival of LGSOC patients was 95.58 (73.37–117.79) months while the median Progression free survival (PFS) was 56.54 (38.15–74.94) months. Primary cytoreductive surgery is still the cornerstone of the management of LGSOC patients. Neoadjuvant chemotherapy could be a predictor of worse progression-free survival in LGSOC patients presented with advanced disease stage.


Keywords

Ovarian cancer; Low grade serous; Serous ovarian cancer; Cytoreductive surgery; Interval debulking; Neoadjuvant chemotherapy


Cite and Share

Mohammad Zuhdy,Mohamed Abdelkhalek,Khaled Gaballa,Mohamed Hamdy,Basel Refky. Prognostic factors and clinical hallmarks of low grade serous ovarian carcinoma: a single center study. European Journal of Gynaecological Oncology. 2023. 44(6);98-104.

References

[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018; 68: 394–424.

[2] Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the national population-based cancer registry program. Journal of Cancer Epidemiology. 2014; 2014: 437971.

[3] Kang JH, Lai YL, Cheng WF, Kim HS, Kuo KT, Chen YL, et al. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan. Scientific Reports. 2020; 10: 20012.

[4] Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, et al. Grading ovarian serous carcinoma using a two-tier system. The American Journal of Surgical Pathology. 2004; 28: 496–504.

[5] Schmeler KM, Gershenson DM. Low-grade serous ovarian cancer: a unique disease. Current Oncology Reports. 2008; 10: 519–523.

[6] Babaier A, Mal H, Alselwi W, Ghatage P. Low-grade serous carcinoma of the ovary: the current status. Diagnostics. 2022; 12: 458.

[7] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA: A Cancer Journal for Clinicians. 2021; 71: 7–33.

[8] Cree IA, White VA, Indave BI, Lokuhetty D. Revising the who classification: female genital tract tumours. Histopathology. 2020; 76: 151–156.

[9] Gershenson DM. The life and times of low-grade serous carcinoma of the ovary. American Society of Clinical Oncology Educational Book. 2013; 33: e195–e199.

[10] Zwimpfer TA, Tal O, Geissler F, Coelho R, Rimmer N, Jacob F, et al. Low grade serous ovarian cancer—a rare disease with increasing therapeutic options. Cancer Treatment Reviews. 2023; 112: 102497.

[11] Moujaber T, Balleine RL, Gao B, Madsen I, Harnett PR, DeFazio A. New therapeutic opportunities for women with low-grade serous ovarian cancer. Endocrine-Related Cancer. 2022; 29: R1–R16.

[12] Ricciardi E, Baert T, Ataseven B, Heitz F, Prader S, Bommert M, et al. Low-grade serous ovarian carcinoma. Geburtshilfe Und Frauenheilkunde. 2018; 78: 972–976.

[13] Di Lorenzo P, Conteduca V, Scarpi E, Adorni M, Multinu F, Garbi A, et al. Advanced low grade serous ovarian cancer: a retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers. Frontiers in Oncology. 2022; 12: 970918.

[14] Cobb LP, Sun CC, Iyer R, Nick AM, Fleming ND, Westin SN, et al. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: further evidence of relative chemoresistance. Gynecologic Oncology. 2020; 158: 653–658.

[15] Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, Wong KK, et al. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. Journal of Clinical Oncology. 2015; 33: 2675–2682.

[16] Chen M, Jin Y, Bi Y, Yin J, Wang Y, Pan L. A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology. OncoTargets and Therapy. 2014; 7: 1891–1899.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top